Cargando…

Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database

BACKGROUND: Erectile dysfunction (ED) is an adverse effect of many medications. AIM: We used a national pharmacovigilance database to assess which medications had the highest reported frequency of ED. METHODS: The Food and Drug Administration Adverse Event Reporting System (FAERS) was queried to ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan-Marans, Elie, Sandozi, Arshia, Martinez, Mariela, Lee, Jeffrey, Schulman, Ariel, Khurgin, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537247/
https://www.ncbi.nlm.nih.gov/pubmed/35843193
http://dx.doi.org/10.1016/j.esxm.2022.100543
_version_ 1784803156940554240
author Kaplan-Marans, Elie
Sandozi, Arshia
Martinez, Mariela
Lee, Jeffrey
Schulman, Ariel
Khurgin, Jacob
author_facet Kaplan-Marans, Elie
Sandozi, Arshia
Martinez, Mariela
Lee, Jeffrey
Schulman, Ariel
Khurgin, Jacob
author_sort Kaplan-Marans, Elie
collection PubMed
description BACKGROUND: Erectile dysfunction (ED) is an adverse effect of many medications. AIM: We used a national pharmacovigilance database to assess which medications had the highest reported frequency of ED. METHODS: The Food and Drug Administration Adverse Event Reporting System (FAERS) was queried to identify medications with the highest frequency of ED adverse event reports from 2010 to 2020. Phosphodiesterase-5 inhibitors and testosterone were excluded because these medications are often used as treatments for men with ED. The 20 medications with the highest frequency of ED were included in the disproportionality analysis. OUTCOMES: Proportional Reporting Ratios (PRRs) and their 95% confidence intervals were calculated. RESULTS: The 20 medications accounted for 6,142 reports of ED. 5-α reductase inhibitors (5-ARIs) and neuropsychiatric medications accounted for 2,823 (46%) and 2,442 (40%) of these reports respectively. Seven medications showed significant levels of disproportionate reporting with finasteride and dutasteride having the highest PRRs: 110.03 (103.14–117.39) and 9.40 (7.83–11.05) respectively. The other medications are used in a wide variety of medical fields such as cardiology, dermatology, and immunology. CLINICAL IMPLICATIONS: Physicians should be familiar with these medications and understand their respective mechanisms of action, so that they may counsel patients appropriately and improve their quality of life. STRENGTHS AND LIMITATIONS: The strength of the study is its large sample size and that it captures pharmacologic trends on a national level. Quantitative and comparative “real-world” data is lacking for the most common medications associated with ED. The limitation is that the number of reported events does not establish causality and cannot be used to calculate ED incidence rates. CONCLUSION: In a national pharmacovigilance database, 5-ARIs and neuropsychiatric medications had the highest reports of ED adverse effects. There were many other medications used in a variety of medical fields that were also associated with ED. Kaplan-Marans E, Sandozi A, Martinez M, et al. Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database. Sex Med 2022;10:100543.
format Online
Article
Text
id pubmed-9537247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95372472022-10-08 Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database Kaplan-Marans, Elie Sandozi, Arshia Martinez, Mariela Lee, Jeffrey Schulman, Ariel Khurgin, Jacob Sex Med Original Research BACKGROUND: Erectile dysfunction (ED) is an adverse effect of many medications. AIM: We used a national pharmacovigilance database to assess which medications had the highest reported frequency of ED. METHODS: The Food and Drug Administration Adverse Event Reporting System (FAERS) was queried to identify medications with the highest frequency of ED adverse event reports from 2010 to 2020. Phosphodiesterase-5 inhibitors and testosterone were excluded because these medications are often used as treatments for men with ED. The 20 medications with the highest frequency of ED were included in the disproportionality analysis. OUTCOMES: Proportional Reporting Ratios (PRRs) and their 95% confidence intervals were calculated. RESULTS: The 20 medications accounted for 6,142 reports of ED. 5-α reductase inhibitors (5-ARIs) and neuropsychiatric medications accounted for 2,823 (46%) and 2,442 (40%) of these reports respectively. Seven medications showed significant levels of disproportionate reporting with finasteride and dutasteride having the highest PRRs: 110.03 (103.14–117.39) and 9.40 (7.83–11.05) respectively. The other medications are used in a wide variety of medical fields such as cardiology, dermatology, and immunology. CLINICAL IMPLICATIONS: Physicians should be familiar with these medications and understand their respective mechanisms of action, so that they may counsel patients appropriately and improve their quality of life. STRENGTHS AND LIMITATIONS: The strength of the study is its large sample size and that it captures pharmacologic trends on a national level. Quantitative and comparative “real-world” data is lacking for the most common medications associated with ED. The limitation is that the number of reported events does not establish causality and cannot be used to calculate ED incidence rates. CONCLUSION: In a national pharmacovigilance database, 5-ARIs and neuropsychiatric medications had the highest reports of ED adverse effects. There were many other medications used in a variety of medical fields that were also associated with ED. Kaplan-Marans E, Sandozi A, Martinez M, et al. Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database. Sex Med 2022;10:100543. Elsevier 2022-07-14 /pmc/articles/PMC9537247/ /pubmed/35843193 http://dx.doi.org/10.1016/j.esxm.2022.100543 Text en Copyright © 2022 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Kaplan-Marans, Elie
Sandozi, Arshia
Martinez, Mariela
Lee, Jeffrey
Schulman, Ariel
Khurgin, Jacob
Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
title Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
title_full Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
title_fullStr Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
title_full_unstemmed Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
title_short Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
title_sort medications most commonly associated with erectile dysfunction: evaluation of the food and drug administration national pharmacovigilance database
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537247/
https://www.ncbi.nlm.nih.gov/pubmed/35843193
http://dx.doi.org/10.1016/j.esxm.2022.100543
work_keys_str_mv AT kaplanmaranselie medicationsmostcommonlyassociatedwitherectiledysfunctionevaluationofthefoodanddrugadministrationnationalpharmacovigilancedatabase
AT sandoziarshia medicationsmostcommonlyassociatedwitherectiledysfunctionevaluationofthefoodanddrugadministrationnationalpharmacovigilancedatabase
AT martinezmariela medicationsmostcommonlyassociatedwitherectiledysfunctionevaluationofthefoodanddrugadministrationnationalpharmacovigilancedatabase
AT leejeffrey medicationsmostcommonlyassociatedwitherectiledysfunctionevaluationofthefoodanddrugadministrationnationalpharmacovigilancedatabase
AT schulmanariel medicationsmostcommonlyassociatedwitherectiledysfunctionevaluationofthefoodanddrugadministrationnationalpharmacovigilancedatabase
AT khurginjacob medicationsmostcommonlyassociatedwitherectiledysfunctionevaluationofthefoodanddrugadministrationnationalpharmacovigilancedatabase